



Contact:
David Waldman or Justyna Gudaszevska
Crescendo Communications, LLC
Email: mmd@crescendo-ir.com
Tel: +48 693 354 580

**Milestone Medical Commences Sales of CompuFlo® Epidural Disposables
within The Pain and Rehabilitation Medical Group in Torrance, California**

*Follows successful evaluation by Dr. Fabian Proano, MD
including complex thoracic procedures*

Roseland, NJ., May 16, 2023 – Milestone Medical Inc. (WAR: MMD, “the Company”) today announced that it has commenced sales of CompuFlo® Epidural disposables into [The Pain and Rehabilitation Medical Group](#) in Torrance, California. Adoption of the technology by this clinic follows a successful evaluation process by its founder, Dr. Fabian Proano, an interventional pain medicine physician, who is board-certified by the American Board of Anesthesiology in both anesthesiology and pain medicine.

Dr. Proano initially conducted eight cases using the CompuFlo Epidural system, in which he reported 100% success. The evaluation included Epidural Steroid Injection (ESI) procedures within the lumbar, thoracic and cervical thoracic junction of the spine.

Dr. Proano has over 25 years of experience in interventional pain management, regenerative medicine, and adult stem cell therapies. He specializes in performing precise image-guided spinal and joint injections. Dr. Proano is a member of numerous organizations including: The American Medical Association, American Society of Interventional Pain Physicians, North American Spine Society, International Spine Injection Society and The North American Neuromodulation Society. Dr. Proano completed his undergraduate studies at Santa Clara University, and attended medical school at University of Washington School of Medicine in Seattle, Washington. His residency training was in Anesthesiology at Harbor/UCLA Medical Center. Dr. Proano also completed an advanced specialty fellowship in Interventional and Multidisciplinary Pain Management at UCLA Medical Center. Dr. Proano has also served as Medical Director of Pain Management at several hospitals.

Dr. Proano commented, “Having evaluated Milestone’s CompuFlo System within my clinic, I can confidently state it has proven to be a valuable tool in helping navigate the challenging anatomical regions in the thoracic region and cervical thoracic junction. The system is easy to use and provides both audible and visual feedback, including real-time confirmation of epidural placement that enhances both the speed and safety of the procedure, thereby providing a better experience for the provider and patient.”

About Milestone Medical Inc.

Milestone Medical, Inc. (WAR:MMD) has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular

instrument in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS), a technology-focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific's computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the [MLSS brand video](#) or visit milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2022. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.